Strategic decisions will come into the focus of Kai Beckmann after he takes over the CEO role, in our view. We identify the Healthcare segment as being in the focus on improving its growth profile through divestments and acquisitions. Divesting the MS business would boost the segmental sales CAGR to 3.1% from 1.0%. We see more opportunity on the upside and reiterate our Outperform rating with a new target price of € 151.
A director at Gilead Sciences Inc sold 10,000 shares at 139.891USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.